Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Day-to-Day Function Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months

NCT00333281
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 24, 2007 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 4 Interventional Results available

A Study in Erectile Dysfunction

NCT01130532
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Huntsville, Alabama • Lancaster, California • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Auri Super Mushroom Daily Gummies on Cognitive Health

NCT07198399
View directory record Official record
Conditions
Cognitive Decline, Focus Deficit
Interventions
Auri Super Mushroom Daily Gummies
Dietary Supplement
Lead sponsor
Auri Nutrition
Industry
Eligibility
30 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Azimilide Dihydrochloride on Renal Function

NCT00318838
View directory record Official record
Conditions
Healthy
Interventions
Azimilide dihydrochloride, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 2 Interventional

Vitamin D to Slow Progression of Knee Osteoarthritis

NCT00306774
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Vitamin D (cholecalciferol), Placebo
Dietary Supplement
Lead sponsor
Tufts Medical Center
Other
Eligibility
45 Years to 90 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Jul 23, 2026, 2:17 PM EDT
Terminated Phase 2 Interventional Results available

Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

NCT04157088
View directory record Official record
Conditions
Prostatic Cancer, Castration-Resistant
Interventions
Darolutamide (Nubeqa, BAY1841788), Enzalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Portland, Maine • Voorhees Township, New Jersey • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional

Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED

NCT00492635
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction, Physiological
Interventions
Levitra (Vardenafil, BAY38-9456), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
11
States / cities
Laguna Hills, California • Jeffersonville, Indiana • Des Moines, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01323621
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

NCT02832037
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
21
States / cities
Garden Grove, California • Lemon Grove, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

NCT04846868
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
18
States / cities
Garden Grove, California • La Habra, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)

NCT01306422
View directory record Official record
Conditions
Appetite Depressant, Overweight, Body Weight
Interventions
Hoodia gordonii purified extract (H.g.PE), Placebo yogurt drink
Other
Lead sponsor
Unilever R&D
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

NCT06397872
View directory record Official record
Conditions
Renal Impairment
Interventions
100 mg Resmetirom Tablet
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Orlando, Florida • Tampa, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Automated IADL Sensing to Refine Measurement of Older Adult Daily Activity

NCT07585864
View directory record Official record
Conditions
Cognitive Ability General, Functional Abilities
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
75 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00622635
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Normal, Illinois • Shawnee Mission, Kansas • Lafayette, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional

Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

NCT00105547
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
MPC-7869
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
132
States / cities
Alabaster, Alabama • Huntsville, Alabama • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Results available

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

NCT01053962
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg, SP-304 9.0 mg, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
14
States / cities
Mesa, Arizona • Tucson, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional Results available

Effects of Device-assisted Practice of ADL on Arm/Hand Recovery in Individuals With Moderate to Severe Stroke

NCT04077073
View directory record Official record
Conditions
Stroke
Interventions
ReIn-Hand, Robot
Device
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional

Role of Exercise in Diastolic Heart Failure

NCT01047631
View directory record Official record
Conditions
Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
Functional circuit training and lifestyle counseling, Health education and independent walking
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

NCT01627327
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
11
States / cities
Newport Beach, California • Coeur d'Alene, Idaho • Charlotte, North Carolina + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

NCT04846881
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tele-video to Improve Daily Activity

NCT06007664
View directory record Official record
Conditions
Physical Inactivity
Interventions
Tele-Video to Improve Daily Activity
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Compensatory Training to Support Brain Healthy Lifestyle Changes in Those at Risk for Alzheimer's Disease

NCT04118985
View directory record Official record
Conditions
Cognitive Symptom, Pre Senile Dementia, Alzheimer Disease
Interventions
Cognitive rehabilitation and health behavior change intervention, Self-implementation
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 23, 2026, 2:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly

NCT03368872
View directory record Official record
Conditions
Sarcopenia
Interventions
Astaxanthin formulation, Placebo, Exercise training
Other
Lead sponsor
Astavita, Inc.
Industry
Eligibility
65 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Jul 23, 2026, 2:17 PM EDT